April 21st 2009: ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent

ImQuest BioSciences and Arisyn Therapeutics jointly announced today the successful acquisition of funding from the National Institutes of Health to support…

March 20th 2009: Poster Presentation on Arisyn ATI-0810 (Hepatitis C)
Made at 13th ISVHLD meeting

ImQuest BioSciences and Arisyn Therapeutics jointly presented important new results
on ATI-0810 (Formerly PG301029), a novel late stage inhibitor of hepatitis C virus (HCV)
replication, at the 13th ISVHLD meeting held last week in Washington D.C.

December 12th 2008: Poster Presentation on Arisyn ATI-0312 (HIV)
Wins Chairman's Award at HIV DART Conference

November 24th 2008: "Focus on Arisyn" published in the issue of R&D Focus Drug News

R&D Focus Drug News presents an introduction to Arisyn Therapeutics Inc. (“Focus on Arisyn”) in their November 24th issue. The article provides a glimpse into Arisyn’s development plans for its extensive portfolio of small molecule compounds. The issue containing the article may be downloaded from the downloads page.

September 23rd 2008: Arisyn Therapeutics Inc. (Arisyn) Acquires Highly Novel
Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
FREDERICK, MD. -- Arisyn Therapeutics Inc. (Arisyn) announced today day that it has successfully acquired from UAF Technologies and Research, L.L.C. (UTR) a series...

April 15th 2008: ATI-0810 Formerly Know as PG 301029 Inhibits HCV Replication
Through a Novel Late Stage Mechanism of Action
ImQuest scientists Todd B. Parsley, Lu Yang, Robert W. Buckheit Jr.  present results from primary screening of Hepatitis C inhibitor at Twenty-First International...